These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34018458)

  • 21. Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma.
    Saeedian M; Badaracco J; Botros A; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Nov; 29(11):712.e1-712.e7. PubMed ID: 37544410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
    Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
    Blood; 2023 Apr; 141(14):1675-1684. PubMed ID: 36542826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.
    Choe JH; Yu T; Abramson JS; Abou-El-Enein M
    Blood Adv; 2024 Jan; 8(2):484-496. PubMed ID: 38153350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?
    Kharfan-Dabaja MA; Yassine F; Moustafa MA; Iqbal M; Murthy H
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(4):168-175. PubMed ID: 34699774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
    Oluwole OO; Chen JMH; Chan K; Patel AR; Jansen JP; Keeping S; Zheng Y; Snider JT; Locke FL
    Leuk Lymphoma; 2022 Dec; 63(13):3052-3062. PubMed ID: 36048026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study.
    Fowler NH; Dickinson M; Ghosh M; Chen AI; Andreadis C; Tiwari R; Masood A; Ramos R; Jousseaume E; Thieblemont C; Dreyling M; Schuster SJ
    Transplant Cell Ther; 2023 Jan; 29(1):60.e1-60.e4. PubMed ID: 36182104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
    Elmacken M; Peredo-Pinto H; Wang C; Xu Z; Tegenge M; Jaigirdar AA; Theoret MR; Purohit-Sheth T; Kasamon YL
    Clin Cancer Res; 2024 Jun; 30(11):2309-2316. PubMed ID: 38324398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.
    Cartron G; Fox CP; Liu FF; Kostic A; Hasskarl J; Li D; Bonner A; Zhang Y; Maloney DG; Kuruvilla J
    Exp Hematol Oncol; 2022 Mar; 11(1):17. PubMed ID: 35337365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.
    Ogasawara K; Dodds M; Mack T; Lymp J; Dell'Aringa J; Smith J
    Clin Pharmacokinet; 2021 Dec; 60(12):1621-1633. PubMed ID: 34125421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisocabtagene Maraleucel for the treatment of B-cell lymphoma.
    Iragavarapu C; Hildebrandt G
    Expert Opin Biol Ther; 2021 Sep; 21(9):1151-1156. PubMed ID: 34030548
    [No Abstract]   [Full Text] [Related]  

  • 31. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
    Abramson JS; Johnston PB; Kamdar M; Ibrahimi S; Izutsu K; Arnason J; Glass B; Mutsaers P; Lunning M; Braverman J; Liu FF; Crotta A; Montheard S; Previtali A; Guo S; Shi L; Solomon SR
    Blood Adv; 2022 Dec; 6(23):5969-5979. PubMed ID: 36149968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel.
    Olson NE; Ragan SP; Reiss DJ; Thorpe J; Kim Y; Abramson JS; McCoy C; Newhall KJ; Fox BA
    Mol Cancer Ther; 2023 Mar; 22(3):406-418. PubMed ID: 36595660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
    Keating SJ; Gu T; Jun MP; McBride A
    Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
    McGarvey N; Ung B; Carattini T; Imanak K; Lee A; Campbell TB; Patwardhan P
    Adv Ther; 2023 Oct; 40(10):4626-4638. PubMed ID: 37597153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
    Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
    J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
    [No Abstract]   [Full Text] [Related]  

  • 36. [New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment].
    Chiche E; Loschi M
    Bull Cancer; 2022 Sep; 109(9):879-880. PubMed ID: 35717220
    [No Abstract]   [Full Text] [Related]  

  • 37. [Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma].
    Chanut M; Herbaux C
    Bull Cancer; 2023 Oct; 110(10):986-988. PubMed ID: 37661551
    [No Abstract]   [Full Text] [Related]  

  • 38. New Approval for Drug Treating Large B-Cell Lymphoma.
    Aschenbrenner DS
    Am J Nurs; 2022 Oct; 122(10):20-21. PubMed ID: 36136022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.
    Lee D; Goyal A; Wang WL; Ananth S; Lau E; Binkley MS; Bharadwaj S; Dahiya S
    EJHaem; 2024 Feb; 5(1):153-156. PubMed ID: 38406546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.